Literature DB >> 24343651

Chlamydia trachomatis-infected epithelial cells and fibroblasts retain the ability to express surface-presented major histocompatibility complex class I molecules.

Danny Kägebein1, Melanie Gutjahr, Christina Große, Annette B Vogel, Jürgen Rödel, Michael R Knittler.   

Abstract

The obligate intracellular bacterial pathogen Chlamydia trachomatis is the causative agent of a variety of infectious diseases such as trachoma and sexually transmitted diseases. In infected target cells, C. trachomatis replicates within parasitophorous vacuoles and expresses the protease-like activity factor CPAF. Previous studies have suggested that CPAF degrades the host transcription factors RFX5 and NF-κB p65, which are involved in the regulation of constitutive and inducible expression of major histocompatibility complex class I (MHC I). It was speculated that Chlamydia suppresses the surface presentation of MHC I in order to evade an effective immune response. Nevertheless, a recent study suggested that RFX5 and NF-κB p65 may not serve as target substrates for CPAF-mediated degradation, raising concerns about the proposed MHC I subversion by Chlamydia. Hence, we investigated the direct influence of Chlamydia on MHC I expression and surface presentation in infected host cells. By using nine different human cells and cell lines infected with C. trachomatis (serovar D or LGV2), we demonstrate that chlamydial infection does not interfere with expression, maturation, transport, and surface presentation of MHC I, suggesting functional antigen processing in bacterium-infected cells. Our findings provide novel insights into the interaction of chlamydiae with their host cells and should be taken into consideration for the design of future therapies and vaccines.

Entities:  

Mesh:

Year:  2013        PMID: 24343651      PMCID: PMC3958011          DOI: 10.1128/IAI.01473-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  63 in total

1.  Chlamydia.

Authors:  Robert Belland; David M Ojcius; Gerald I Byrne
Journal:  Nat Rev Microbiol       Date:  2004-07       Impact factor: 60.633

Review 2.  MHC class I antigen presentation: learning from viral evasion strategies.

Authors:  Ted H Hansen; Marlene Bouvier
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

3.  Beta interferon is produced by Chlamydia trachomatis-infected fibroblast-like synoviocytes and inhibits gamma interferon-induced HLA-DR expression.

Authors:  J Rödel; A Groh; H Vogelsang; M Lehmann; M Hartmann; E Straube
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Infection of myocytes with chlamydiae.

Authors:  Guqi Wang; Frank Burczynski; Brian Hasinoff; Guangming Zhong
Journal:  Microbiology       Date:  2002-12       Impact factor: 2.777

5.  Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors.

Authors:  Margaret M Madeleine; Tarja Anttila; Stephen M Schwartz; Pekka Saikku; Maija Leinonen; Joseph J Carter; Michelle Wurscher; Lisa G Johnson; Denise A Galloway; Janet R Daling
Journal:  Int J Cancer       Date:  2007-02-01       Impact factor: 7.396

6.  Chlamydia trachomatis as a cause of acute perihepatitis associated with pelvic inflammatory disease.

Authors:  K Dalaker; H Gjønnaess; G Kvile; A Urnes; G Anestad; T Bergan
Journal:  Br J Vener Dis       Date:  1981-02

7.  Action of oligomycin on cultured mammalian cells. Permeabilization to translation inhibitors.

Authors:  M J Otero; L Carrasco
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

8.  Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity.

Authors:  Xiaozhou Jiang; Caixia Shen; Jose Rey-Ladino; Hong Yu; Robert C Brunham
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

9.  Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones.

Authors:  J U Igietseme; D M Magee; D M Williams; R G Rank
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Restricted fusion of Chlamydia trachomatis vesicles with endocytic compartments during the initial stages of infection.

Authors:  Marci A Scidmore; Elizabeth R Fischer; Ted Hackstadt
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

View more
  4 in total

1.  Enhanced Direct Major Histocompatibility Complex Class I Self-Antigen Presentation Induced by Chlamydia Infection.

Authors:  Erik D Cram; Ryan S Simmons; Amy L Palmer; William H Hildebrand; Daniel D Rockey; Brian P Dolan
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

2.  Chlamydia trachomatis Infection Impairs MHC-I Intracellular Trafficking and Antigen Cross-Presentation by Dendritic Cells.

Authors:  Diego Del Balzo; Anahí Capmany; Ignacio Cebrian; María Teresa Damiani
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

3.  Chlamydial clinical isolates show subtle differences in persistence phenotypes and growth in vitro.

Authors:  Mark Thomas; Amba Lawrence; Samuel Kroon; Lenka A Vodstrcil; Samuel Phillips; Jane S Hocking; Peter Timms; Wilhelmina M Huston
Journal:  Access Microbiol       Date:  2021-02-19

4.  Conjunctival scarring in trachoma is associated with the HLA-C ligand of KIR and is exacerbated by heterozygosity at KIR2DL2/KIR2DL3.

Authors:  Chrissy H Roberts; Sandra Molina; Pateh Makalo; Hassan Joof; Emma M Harding-Esch; Sarah E Burr; David C W Mabey; Robin L Bailey; Matthew J Burton; Martin J Holland
Journal:  PLoS Negl Trop Dis       Date:  2014-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.